JPH0637450B2 - エチル−３−（２−エチル−２，２−ジメチルヒドラジニウム）−プロピオン酸塩 - Google Patents
エチル−３−（２−エチル−２，２−ジメチルヒドラジニウム）−プロピオン酸塩Info
- Publication number
- JPH0637450B2 JPH0637450B2 JP63068323A JP6832388A JPH0637450B2 JP H0637450 B2 JPH0637450 B2 JP H0637450B2 JP 63068323 A JP63068323 A JP 63068323A JP 6832388 A JP6832388 A JP 6832388A JP H0637450 B2 JPH0637450 B2 JP H0637450B2
- Authority
- JP
- Japan
- Prior art keywords
- ethyl
- arrhythmias
- propionate
- compounds
- fibrillation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000001875 compounds Chemical class 0.000 description 37
- 206010003119 arrhythmia Diseases 0.000 description 28
- 230000006793 arrhythmia Effects 0.000 description 28
- 206010061592 cardiac fibrillation Diseases 0.000 description 24
- 230000000694 effects Effects 0.000 description 20
- 230000003288 anthiarrhythmic effect Effects 0.000 description 18
- 230000002600 fibrillogenic effect Effects 0.000 description 17
- 206010061216 Infarction Diseases 0.000 description 16
- 230000000302 ischemic effect Effects 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 208000028867 ischemia Diseases 0.000 description 11
- PVBQYTCFVWZSJK-UHFFFAOYSA-N meldonium Chemical compound C[N+](C)(C)NCCC([O-])=O PVBQYTCFVWZSJK-UHFFFAOYSA-N 0.000 description 11
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 10
- 229960004194 lidocaine Drugs 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 230000000747 cardiac effect Effects 0.000 description 8
- 229960002937 meldonium Drugs 0.000 description 8
- 238000009472 formulation Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 206010058156 Reperfusion arrhythmia Diseases 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 230000010410 reperfusion Effects 0.000 description 6
- 230000033764 rhythmic process Effects 0.000 description 6
- 206010011086 Coronary artery occlusion Diseases 0.000 description 5
- 208000000418 Premature Cardiac Complexes Diseases 0.000 description 5
- 208000034189 Sclerosis Diseases 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 239000003416 antiarrhythmic agent Substances 0.000 description 5
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 206010015856 Extrasystoles Diseases 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 230000006735 deficit Effects 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 208000031225 myocardial ischemia Diseases 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 210000004351 coronary vessel Anatomy 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000004872 arterial blood pressure Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- XTLNYNMNUCLWEZ-UHFFFAOYSA-N ethanol;propan-2-one Chemical compound CCO.CC(C)=O XTLNYNMNUCLWEZ-UHFFFAOYSA-N 0.000 description 2
- -1 ethyl halide Chemical class 0.000 description 2
- WHRIKZCFRVTHJH-UHFFFAOYSA-N ethylhydrazine Chemical compound CCNN WHRIKZCFRVTHJH-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-O hydrazinium(1+) Chemical class [NH3+]N OAKJQQAXSVQMHS-UHFFFAOYSA-O 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 230000007383 nerve stimulation Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 208000003663 ventricular fibrillation Diseases 0.000 description 2
- 206010047302 ventricular tachycardia Diseases 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- GICIECWTEWJCRE-UHFFFAOYSA-N 3,4,4,7-tetramethyl-2,3-dihydro-1h-naphthalene Chemical compound CC1=CC=C2C(C)(C)C(C)CCC2=C1 GICIECWTEWJCRE-UHFFFAOYSA-N 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- OKIBNKKYNPBDRS-UHFFFAOYSA-N Mefluidide Chemical compound CC(=O)NC1=CC(NS(=O)(=O)C(F)(F)F)=C(C)C=C1C OKIBNKKYNPBDRS-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- ZSXLAJUILPSSLE-UHFFFAOYSA-N amino(trimethyl)azanium Chemical compound C[N+](C)(C)N ZSXLAJUILPSSLE-UHFFFAOYSA-N 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000002763 arrhythmic effect Effects 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000003683 cardiac damage Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000002057 chronotropic effect Effects 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000037024 effective refractory period Effects 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- YOZNOKNEBAAMKA-UHFFFAOYSA-N ethyl 3-(2,2-dimethylhydrazinyl)propanoate Chemical compound CCOC(=O)CCNN(C)C YOZNOKNEBAAMKA-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000036279 refractory period Effects 0.000 description 1
- 210000005241 right ventricle Anatomy 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU4217356 | 1987-03-25 | ||
| SU874217356A SU1680693A1 (ru) | 1987-03-25 | 1987-03-25 | Этил-3-(2,2-диметил-2-этилгидразиний)пропионат иодистый, про вл ющий антиаритмическую активность |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPS6459A JPS6459A (en) | 1989-01-05 |
| JPH0159A JPH0159A (ja) | 1989-01-05 |
| JPH0637450B2 true JPH0637450B2 (ja) | 1994-05-18 |
Family
ID=21293660
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP63068323A Expired - Lifetime JPH0637450B2 (ja) | 1987-03-25 | 1988-03-24 | エチル−３−（２−エチル−２，２−ジメチルヒドラジニウム）−プロピオン酸塩 |
Country Status (7)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1667955A2 (en) * | 2003-07-28 | 2006-06-14 | SmithKline Beecham Corporation | Cycloalkylidene compounds as modulators of the estrogen receptor |
| DK1667960T3 (da) * | 2003-08-04 | 2008-06-09 | Grindeks Jsc | Meldoniumsalte, fremgangsmåde til deres fremstilling og farmaceutisk sammensætning på deres basis |
| LV14345B (lv) * | 2009-10-22 | 2011-07-20 | Grindeks, A/S | 4-[Etil(dimetil)amonija]butanoāts un tā izmantošana kardiovaskulāro slimību ārstēšanai |
| GEP20156373B (en) * | 2011-04-27 | 2015-09-25 | Grindeks Jsc | Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease |
| RU2458690C1 (ru) * | 2011-05-31 | 2012-08-20 | Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" | Производное 3-(2,2,2-триметилгидразиний) пропионата - 5-бромникотинат 3-(2,2,2-триметилгидразиний) пропионат калия, обладающее противоишемической активностью |
| CN109879773A (zh) * | 2019-03-08 | 2019-06-14 | 东力（南通）化工有限公司 | 一种3-（2-乙基-2,2-二甲基肼基）丙酸乙酯碘盐原料药制备技术的改进方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU997646A1 (ru) * | 1978-11-27 | 1983-02-23 | Ордена Трудового Красного Знамени Институт Органического Синтеза Ан Латвсср | Кормова добавка |
| IT1210935B (it) * | 1981-09-17 | 1989-09-29 | Inst Orch Sinteza Akademi Nauk | Composizione farmaceutica per il trattamento di malattie cardiovascolari. |
| CA1224490A (en) * | 1983-05-18 | 1987-07-21 | Gunar A. Bremanis | 3(2,2,2-trisubstituted hydrazinium) propionates |
| SU1247012A1 (ru) * | 1983-07-13 | 1986-07-30 | Ордена Трудового Красного Знамени Институт Органического Синтеза Ан Латвсср | Замещенные 3-гидразинопропионаты или их фармацевтически пригодные соли,обладающие антиаритмической активностью |
-
1987
- 1987-03-25 SU SU874217356A patent/SU1680693A1/ru active
-
1988
- 1988-03-24 GB GB8807042A patent/GB2203147B/en not_active Expired - Fee Related
- 1988-03-24 JP JP63068323A patent/JPH0637450B2/ja not_active Expired - Lifetime
- 1988-03-24 CH CH1118/88A patent/CH674360A5/de not_active IP Right Cessation
- 1988-03-24 FR FR8803888A patent/FR2612922A1/fr not_active Withdrawn
- 1988-03-25 DE DE3810264A patent/DE3810264A1/de active Granted
-
1989
- 1989-10-30 US US07/428,901 patent/US5017611A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US5017611A (en) | 1991-05-21 |
| GB2203147B (en) | 1991-07-03 |
| JPS6459A (en) | 1989-01-05 |
| DE3810264C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1990-06-28 |
| GB8807042D0 (en) | 1988-04-27 |
| SU1680693A1 (ru) | 1991-09-30 |
| GB2203147A (en) | 1988-10-12 |
| CH674360A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1990-05-31 |
| FR2612922A1 (fr) | 1988-09-30 |
| DE3810264A1 (de) | 1988-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nademanee et al. | Antiarrhythmic efficacy and electrophysiologic actions of amiodarone in patients with life-threatening ventricular arrhythmias: potent suppression of spontaneously occurring tachyarrhythmias versus inconsistent abolition of induced ventricular tachycardia | |
| Goldreyer et al. | The essential role of atrioventricular conduction delay in the initiation of paroxysmal supraventricular tachycardia | |
| SCHERLAG et al. | Characterization and localization of ventricular arrhythmias resulting from myocardial ischemia and infarction | |
| Ovize et al. | Coronary cyclic flow variations" precondition" ischemic myocardium. | |
| Russell et al. | Transmembrane potential changes and ventricular fibrillation during repetitive myocardial ischaemia in the dog | |
| JPH0637450B2 (ja) | エチル−３−（２−エチル−２，２−ジメチルヒドラジニウム）−プロピオン酸塩 | |
| HU224033B1 (hu) | Szotalol dextro- és levo-izomereinek keverékét tartalmazó gyógyszerkészítmény | |
| JPH0159A (ja) | エチル−３−（２−エチル−２，２−ジメチルヒドラジニウム）−プロピオン酸塩 | |
| Fagbemi et al. | Antiarrhythmic actions of meptazinol, a partial agonist at opiate receptors, in acute myocardial ischaemia | |
| US5470852A (en) | Tetrahydroprotoberberine quaternary ammonium compounds useful in for treating arrhythmia | |
| Fiedler | Reduction of myocardial infarction and dysrhythmic activity by nafazatrom in the conscious rat | |
| US4451485A (en) | Treatment of cardio-vascular diseases with 3-(2,2,2-trimethylhydrazinium) propionate dihydrate | |
| Wainwright et al. | Effects of R-PIA, a selective A1 adenosine agonist, on haemodynamics and ischaemic arrhythmias in pigs | |
| US3968205A (en) | Infusion solution for the treatment of tachycardiac disturbances of heart rhythm and use thereof | |
| KNIFFEN et al. | The comparative antiarrhythmic actions of lidocaine and its quarternary derivative, methyl lidocaine | |
| Miller et al. | Electrocardiographic changes following the intravenous administration of magnesium sulfate: III. Combined effect with digitalis | |
| Naito et al. | Role of early cycle ventricular extrasystoles in initiation of ventricular tachycardia and fibrillation: evaluation of the R on T phenomenon during acute ischemia in a canine model | |
| RU2180583C1 (ru) | Лекарственный препарат для лечения различных форм нарушения ритма сердца | |
| Yamane et al. | Pseudo sinus rhythm originating from the left superior pulmonary vein in a patient with paroxysmal atrial fibrillation | |
| Barrett et al. | The electrophysiologic effects of intravenous lidocaine in the Wolff-Parkinson-White syndrome | |
| DE60119336T2 (de) | Verwendungen von thaliporphin oder seinen derivaten in der behandlung von herzkrankheiten und seine herstellung | |
| JPH05208993A (ja) | 虚血治療用製薬組成物 | |
| Dussault et al. | Electrocardiography for diagnosis and control of efficacy of oral quinidine sulfate in a case of atrial fibrillation in a Holstein cow | |
| SU1120654A1 (ru) | Соли мезидидов @ -пиперидинкарбоновых кислот, обладающие местноанестезирующей, антиаритмической и антифибрилл торной активностью, и мезидиды @ -пиперидинкарбоновых кислот в качестве промежуточных продуктов дл синтеза солей мезидидов @ -пиперидинкарбоновых кислот | |
| Gould et al. | Electrophysiological properties of phentolamine in man. |